Newsroom


Alnylam Receives Approval of ONPATTRO™ (patisiran) in Europe

Alnylam Receives Approval of ONPATTRO™ (patisiran) in Europe

Alnylam Pharmaceuticals, Inc, announced recently that the European Commission (EC) has granted marketing authorization for ONPATTRO (patisiran) for the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis in adults with stage 1 or stage 2 polyneuropathy. ONPATTRO is the first-ever RNA interference (RNAi) therapeutic to be approved in the European Union.

Read the press release here.